Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Recurrent or refractory advanced renal cell carcinoma (RCC) after two or more previous systemic treatments.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：13
Adult patients with locally advanced or metastatic ROS1 positive non-small cell lung cancer (NSCLC).【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
Non small cell lung cancer with MET gene exon 14 mutation positive and unresectable progression and recurrence.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：8
iIndicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease .【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：0
Deucravacitinib is suitable for treating plaque psoriasis.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：17
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：15
Used for relapsed/refractory mantle cell lymphoma and other B-cell malignancies.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：5
Adult patients with moderate to severe rheumatoid arthritis (RA) who have insufficient or intolerant response to various disease modifying antirheumatic drugs (DMARD).【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：5
Daprodustat is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：9
The first-line treatment for metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21L858R substitution mutation.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：16
Used for the treatment of relapsed or refractory FLT3-ITD mutation positive acute myeloid leukemia.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：9
Valcyte treatment for cytomegalovirus infection.【more】
Article source：Captain MedicineRelease date：2026-01-05Recommended：10
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3672024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：802025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：902025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：932025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
